Zealand Phar­ma blue­prints an $86M IPO on Nas­daq as it ma­neu­vers its way in­to PhI­II

Copen­hagen-based Zealand Phar­ma is fol­low­ing a clear­ly blazed trail from Eu­rope to Nas­daq in search of an IPO that can help fund a pair of late-stage drugs.

Fol­low­ing the up­beat re­sults for AC Im­mune (Switzer­land) $ACIU and Ar­genx (Bel­gium) $ARGX ear­li­er this year, the Dan­ish biotech filed an F-1 for an $86 mil­lion IPO.

Zealand out­li­censed lixise­n­atide to Sanofi and now has high hopes for two drugs head­ed in­to Phase III test­ing. The biotech, though, will have con­sid­er­able ex­plain­ing to do to woo in­vestors to their Nas­daq play. A month ago the Swiss biotech re­turned rights to el­siglu­tide for the treat­ment of chemother­a­py-in­duced di­ar­rhea af­ter it failed a key Phase IIb study last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER